Call for Abstracts: DIA EuroMeeting 2017

DIA29 - 31 March 2017, Glasgow, UK.
The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.

DIA invites you to submit presentation, session and tutorial abstracts for the 29th Annual EuroMeeting in Glasgow, UK. You may submit more than one abstract. Abstracts should fall under one of the themes detailed bellow.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and managing the session (including the facilitation of question and answers from the audience). PowerPoint presentations are required. We encourage innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area; the abstract author is considered the speaker. A PowerPoint presentation is required. If selected, the abstract will consist of a single presentation which will fit within a session.

Tutorial Abstract
A tutorial is a 'hands-on', interactive learning experience. A tutorial consists of 3 hours of instruction with a 30-minute break. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organisation as the author.

Hot-Topic / Stand-Alone Sessions
Each year, there are a number of sessions which do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes / topics outlined, you may submit it for consideration as a hot-topic / stand-alone presentation or session.

How to maximise the probability of your abstract being accepted
Abstracts will be selected by the EuroMeeting Programme Committee. The theme leaders have indicated the strategic topics they would like to address.

  • Focus your abstracts on the proposed topics in this flyer. If your abstract clearly does not fit, submit it as a hot topic / stand-alone presentation or session
  • Your abstract should be as clear and as detailed as possible to enable the theme leaders to make a judgement on its suitability for the programme
  • Abstracts must be non-promotional and non-commercial in order to be considered

If you have any questions about abstract submission, please email the EuroMeeting team: This email address is being protected from spambots. You need JavaScript enabled to view it.

The deadline for submitting abstracts is Monday, 27 June 2016.

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2017/03/29th-annual-euromeeting

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...